Engineering mammalian cell lines for biologics and gene therapies is a complex and time-consuming process, often requiring extensive trial-and-error to achieve optimal production yields and desired therapeutic properties. Traditional methods lack the precision and scalability needed to efficiently design and manufacture advanced therapies.

Asimov offers an integrated platform that combines synthetic biology, biophysical simulations, and machine learning to streamline the engineering of mammalian cell lines. The platform enables users to design, simulate, and optimize genetic systems for various cell types and applications. By providing engineered host cells, validated genetic parts, and cloud-based design software, Asimov facilitates the intelligent design of living systems for advanced therapeutic development. The platform supports the production of protein therapeutics, viral vectors for gene therapy, and programmable medicines with precise transgene expression control.

Engineered, GMP-grade host cell lines with supporting regulatory documentation

Extensive library of experimentally validated genetic parts, including transposases, expression vectors, and inducible systems

Cloud-based software for designing, simulating, and optimizing genetic systems

AI-driven models for cell line and bioprocess design tailored to specific molecules

CHO Edge system routinely achieves titers of 5-11 g/L across modalities

AAV Edge suite of AI models, host cells, and genetic tools for end-to-end gene therapy development

LV Edge Packaging System to optimize lentivirus production

Asimov's platform is designed for biotech companies, pharmaceutical firms, and research institutions involved in the development and manufacturing of biologics, gene therapies, and other advanced therapeutics.